Renaissance Capital logo

ACELYRIN Priced, Nasdaq: SLRN

Late-stage biotech developing in-licensed therapies for inflammatory diseases.

Industry: Health Care

Latest Trade: $4.68 +0.08 (+1.7%)

First Day Return: +30.6%

Return from IPO: -74.4%

Industry: Health Care

ACELYRIN is a late-stage clinical biopharma company focused on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. Our initial focus is on the treatment of diseases with pathology related to excess activation of the immune system, an area where our management and team bring industry-leading expertise. We acquired our portfolio of product candidates with the intent to develop and commercialize novel therapies that we believe may provide the opportunity to offer clinically meaningful, differentiated benefits for patients by improving upon the efficacy and/or safety of existing therapeutics directed against established targets, such as currently marketed anti-interleukin (IL)-17A agents, or by targeting new modalities. In each case, our strategy is to identify candidates we believe are “diamonds in the rough,” where, based on molecule characteristics, our collective experience and expertise, and the evolving scientific and medical understanding, we can establish a clinical development plan that tests our hypotheses as to what those benefits could mean for patients. Subsequently, we plan to utilize the results from initial clinical trials and the learnings we obtain from emerging biology to potentially expand the application of our candidates to other indications in which there are significant unmet needs.
more less
IPO Data
IPO File Date 04/13/2023
Offer Price $18.00
Price Range $16.00 - $18.00
Offer Shares (mm) 30.0
Deal Size ($mm) $540
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date 05/04/2023
Offer Price $18.00
Price Range $16.00 - $18.00
Offer Shares (mm) 30.0
Deal Size ($mm) $540
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
Underwriters
Morgan Stanley
Jefferies
more
Company Data
Headquarters Agoura Hills, CA, United States
Founded 2020
Employees 51
Website www.acelyrin.com

ACELYRIN (SLRN) Performance